| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.069 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |